Cadrenal Therapeutics
CVKD
6 hedge funds and large institutions have $408K invested in Cadrenal Therapeutics in 2023 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 4 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
0.28% less ownership
Funds ownership: 0.57% → 0.28% (-0.28%)
33% less funds holding
Funds holding: 9 → 6 (-3)
46% less capital invested
Capital invested by funds: $752K → $408K (-$344K)
75% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$41.8K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$8 |
| 3 |
Wells Fargo
San Francisco,
California
|
+$8 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$300K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$19.8K |
| 3 |
VF
Virtu Financial
New York
|
-$17K |
| 4 |
TSS
Two Sigma Securities
New York
|
-$7.37K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$92 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AC
1
Armistice Capital
New York
| $307K | -$300K | -37,867 | -58% |
|
|
2
Renaissance Technologies
New York
| $59K | +$41.8K | +5,273 | New |
|
3
Geode Capital Management
Boston,
Massachusetts
| $27.6K | – | – | – |
|
|
BFO
4
Biltmore Family Office
Charlotte,
North Carolina
| $8.14K | – | – | – |
|
|
TRCT
5
Tower Research Capital (TRC)
New York
| $6.29K | +$8 | +1 | +0.2% |
|
|
6
Wells Fargo
San Francisco,
California
| $39 | +$8 | +1 | +33% |
|
|
7
Citadel Advisors
Miami,
Florida
| – | -$19.8K | -1,941 | Closed |
|
|
VF
8
Virtu Financial
New York
| – | -$17K | -1,698 | Closed |
|
|
TSS
9
Two Sigma Securities
New York
| – | -$7.37K | -722 | Closed |
|
|
10
UBS Group
Zurich,
Switzerland
| – | -$92 | -9 | Closed |
|
CVKD Hedge Fund Activity: Q4 2023 in Review
6 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Cadrenal Therapeutics (CVKD) for Q4 2023, worth a combined $408K — down 46% from $752K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of CVKD and 1 opened new positions — a net loss of 3 holders — while 1 trimmed existing stakes and 2 added.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $41.8K. The largest seller was Armistice Capital, cutting an estimated $300K.
- 6 institutional investors held Cadrenal Therapeutics (CVKD) as of Q4 2023, down from 9 in Q3 2023.
- Funds reported $408K of Cadrenal Therapeutics stock for Q4 2023, down 46% quarter-over-quarter.
- 1 fund opened new Cadrenal Therapeutics positions in Q4 2023 and 4 closed out, a net change of -3 holders.
- The largest Cadrenal Therapeutics buyer in Q4 2023 was Renaissance Technologies, an estimated $41.8K added.
- The largest Cadrenal Therapeutics seller in Q4 2023 was Armistice Capital, an estimated $300K sold.
Based on aggregated 13F filings for Q4 2023.